{"prompt": "['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', 'a) The research procedures that are described in the study-related documents, including study', 'deviations, as well as issues related to compromise of participant privacy or confidentiality', 'of data.', 'b) The characteristics of the population being studied.', 'Related or possibly related to participation in the research (possibly related means there is a', 'reasonable possibility that the incident, experience, or outcome may have been caused by the', 'procedures involved in the research).', 'Suggests that the research places participants or others at a greater risk of harm (including', 'physical, psychological, economic, or social harm) than was previously known or recognized', 'and if in relation to an AE is also deemed Serious per Section 10.2.', '10.5.2 Reporting Unanticipated Problems', 'Unanticipated problem reporting will begin at the time of participant consent. The Reportable New', 'Information (RNI) Form will be submitted to CRS Compliance Office within 1 business day of', 'becoming aware of the Unanticipated Problem. After review, CRS Compliance will submit the', 'RNI to the IRB.', 'When becoming aware of new information about the Unanticipated Problem, submit this updated', 'information to CRS Compliance with an updated Reportable New Information Form. The site', 'Investigator or designated research personnel will report all unanticipated problems, whether', 'related or unrelated to the investigational agent(s) to the IRB in accordance with their local', 'institutional guidelines.', '10.6 SAFETY STOPPING RULE', 'If 20% of patients randomized to the PDT arm fail treatment and require salvage surgery at any', 'one institution with 50% of their accrual target, the RPCI DSMB will suspend the study for further', 'evaluation.', '10.7 FDA REPORTING', 'This protocol is being conducted under a RPCI IND, and RPCI will be responsible for reporting', \"certain AEs or Unanticipated Problems to the FDA. RPCI's Compliance Office will report\", 'Network Site reports to the FDA.', 'The following describes the FDA reporting requirements by timeline for AEs and new safety', 'findings that meet the criteria outlined below:', 'Within 7 Calendar Days', 'Any adverse event that meets ALL the following criteria:', 'Related or possibly related to the use of the study drug;', 'Unexpected; and', 'Fatal or life-threatening.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 41 of 64']['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', 'Within 15 Calendar Days', 'Any adverse event that meets ALL the following criteria:', 'Related or possibly related to the use of the study drug;', 'Unexpected; and', 'Serious but not fatal or life-threatening.', 'Or meets ANY of the following criteria:', 'A previous adverse event that is not initially deemed reportable but is later found to fit the', 'criteria for reporting (report within 15 days from when event was deemed reportable).', 'Any findings from other studies, including epidemiological studies, pooled analysis of', 'multiple studies, or other clinical studies conducted with the study drug that suggest a', 'significant risk in humans exposed to the drug.', 'Any findings from animal or in vitro testing that suggest a significant risk for human', 'participants including reports of mutagenicity, teratogenicity, or carcinogenicity or reports', 'of significant organ toxicity at or near the expected human exposure.', 'Any clinically important increase in the rate of occurrence of a serious, related or possibly', 'related adverse event over that listed in the protocol or investigator brochure.', 'Sponsors are also required to identify in IND safety reports, all previous reports concerning similar', 'adverse events and to analyze the significance of the current event in the light of the previous', 'reports.', 'Reporting Process', 'The principal investigator or designee will complete and submit a FDA Form 3500A MedWatch', 'for any event that meets the above criteria. Forms will be submitted to the CRS Compliance Office', 'via email: CRSCompliance@RoswellPark.org.', '11 DATA AND SAFETY MONITORING BOARD', 'The RPCI Data and Safety Monitoring Board will assess the progress of the study, the safety data,', 'and critical efficacy endpoints. The DSMB will review the study annually and will make', 'recommendations that include but not limited to; (a) continuation of the study, (b) modifications', 'to the design (c) or termination of the study.', '12 STATISTICAL METHODOLOGY', 'The primary objective of this study is test the non-inferiority of PDT to standard of care by', 'comparing the rate of tumor response after PDT to those obtained after surgery, at 24 months post', 'treatment. The secondary objectives are to compare QoL after PDT or surgery at 6, 12, 18, and 24', 'months post-procedure, and to assess the toxicity using the CTEP NCI Common Terminology', 'Criteria for Adverse Events (CTCAE Version 4.0).', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 42 of 64']\n\n###\n\n", "completion": "END"}